MaxCyte Inc. (MXCT)
MaxCyte Inc. (MXCT) Stock Price, Analysis & Data
| Bid | 0.96 |
| Market Cap | 134.94M |
| Revenue (ttm) | 32.29M |
| Net Income (ttm) | -39.12M |
| Beta | 1.49 |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.38 |
| P/B (ttm) | 0.80 |
| P/S (ttm) | 4.18 |
| Earnings Date | Aug 12, 2026 |
| Ask | 1.57 |
| Volume | 1,270,090 |
| Avg. Volume (20D) | 1,267,982 |
| Open | 1.35 |
| Previous Close | 1.24 |
| Day's Range | 1.22 - 1.36 |
| 52-Week Range | 0.64 - 1.86 |
| Analyst | n/a |
| Price Target | 4.5 (257.14%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for ...
Financial Performance
In 2025, MaxCyte's revenue was 33.03M, a decrease of -14.5% compared to the previous year's 38.63M. Earnings were -44.63M, an increase of 8.71%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for MXCT stock is "null". The 12-month stock price forecast is 4.5, which is upside of 257.14% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
